



## **SPANISH SECURITIES MARKET COMMISSION (CNMV)**

CLÍNICA BAVIERA, S.A., on behalf of Aier Eye International (Europe), S.L.U. (the “**Selling Shareholder**”) in compliance with the requirements set forth in article 17 of Regulation (EU) 596/2014 and article 228 of the restated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, notifies the following,

### **SIGNIFICANT INFORMATION ANNOUNCEMENT**

Further to the significant information announcement released by the Company on 2 April 2018 (register number 263590) whereby the **Selling Shareholder** stated its intention to explore the possibility of increasing the free float of Clínica Baviera, S.A. (the **Issuer**) , it is reported that Ahorro Corporación Financiera, S.V., S.A.U., acting as sole bookrunner, is today conducting a private placement among qualified investors of a block of 1,141,531 shares of the Issuer, representing approximately 7% of its issued share capital (the “**Shares**”), on behalf of the Selling Shareholder, a company controlled by Aier Eye International (Hong Kong) Limited, which is in turn controlled by Aier Eye Hospital Group Co. LTD, by way of an accelerated bookbuilding (“**ABB**”), that is expected to be completed no later than tomorrow morning.

The terms of the ABB, including the final size and the definitive price per share, will be determined upon completion of the accelerated bookbuilding process and will be notified in due course through a further significant information announcement.

Following the ABB, the Selling Shareholder or affiliates thereof will continue to hold 13,017,979 shares of the Issuer, representing approximately 79.83% of its issued share capital.

Subject to certain customary exceptions, the Selling Shareholder has undertaken not to dispose of its ordinary shares except with the prior consent of the sole bookrunner for a period of 90 days.

Madrid, 3 July 2018.

Antonio Peral Ortiz de la Torre

---

Deputy Secretary of the Board of Directors

## **IMPORTANT INFORMATION**

This document is not for publication or distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan or any country or jurisdiction where the distribution of such document is restricted by law.

The securities herein referred to have not been and will not be registered under the U.S. Securities act of 1933 or under other supervisory authority of any State or jurisdiction of the United States of America, or the applicable securities laws of Canada, Australia or Japan. Accordingly, the securities may not be offered, exercised or sold in the United States, Canada, Australia or Japan, or in any other country or jurisdiction other than in compliance with the applicable laws of that country or jurisdiction, or on behalf or for the benefit of any person in the United States, Canada, Australia or Japan.